Unknown

Dataset Information

0

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.


ABSTRACT: Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition.

SUBMITTER: Baburaj G 

PROVIDER: S-EPMC7670900 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7537958 | BioStudies
2020-01-01 | S-EPMC7565788 | BioStudies
2020-01-01 | S-EPMC7319627 | BioStudies
2020-01-01 | S-EPMC7338708 | BioStudies
2020-01-01 | S-EPMC7544403 | BioStudies
2020-01-01 | S-EPMC7211915 | BioStudies
2021-01-01 | S-EPMC7789899 | BioStudies
2021-01-01 | S-EPMC7678434 | BioStudies
2020-01-01 | S-EPMC7468567 | BioStudies
2021-01-01 | S-EPMC7859465 | BioStudies